Sangamo Therapeutics Auctions Key Assets for $163.55M in Bankruptcy Sale
Event summary
- Sangamo Therapeutics concluded a court-supervised auction, selling key assets for $163.55M in cash and up to $100M in milestones.
- PTC Therapeutics acquired the Fabry disease program (isaralgagene civaparvovec) for $111M upfront plus $100M in potential milestones.
- Eli Lilly purchased Sangamo’s capsid delivery, zinc finger, and MINT platforms along with the prion disease program for $50M.
- Deals are subject to U.S. Bankruptcy Court approval, with expected closings in Q3 2026.
The big picture
Sangamo’s asset auction reflects the strategic realignment of a biotech company under financial distress, offloading key programs to larger players like PTC Therapeutics and Eli Lilly. The deals highlight the ongoing consolidation in gene therapy and platform technologies, as well as the challenges of sustaining pipeline development amid bankruptcy proceedings.
What we're watching
- Regulatory Approval
- Whether the U.S. Bankruptcy Court will approve the asset sales as proposed and on schedule.
- Milestone Payments
- The likelihood of PTC Therapeutics achieving FDA milestones for the Fabry disease program, unlocking up to $100M in additional payments.
- Remaining Asset Sales
- The pace at which Sangamo can monetize its remaining assets, including ST-503 and giroctocogene fitelparvovec.
Related topics